MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

Kodu・Aktsiate loetelu・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Avatud

12.54 -8.4

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.32

Max

13.76

Põhinäitajad
By Trading Economics
Sissetulek	-23M -14M
Müük	-22M 72M
Kasumimarginaal	-18.944
Töötajad	624
EBITDA	-23M -6.4M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+40.57% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. apr 2026

Turustatistika
By TradingEconomics
Turukapital	-639M 2.2B
Eelmine avamishind	20.94
Eelmine sulgemishind	12.54

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

8.81 / 10.18 Toetus ja vastupanu

Adaptive Biotechnologies Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9. apr 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9. apr 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9. apr 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9. apr 2026, 20:57 UTC

Uudisväärsed sündmused

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9. apr 2026, 20:55 UTC

Tulu

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. apr 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Rowan Digital Infrastructure Announces Strategic Recapitalization

9. apr 2026, 20:25 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. apr 2026, 19:30 UTC

Uudisväärsed sündmused

How Digital Currencies Have Helped Iran -- WSJ

Võrdlus sarnastega

Hinnamuutus

Adaptive Biotechnologies Corp Prognoos

Hinnasiht

By TipRanks

40.57% tõus

12 kuu keskmine prognoos

Keskmine 20.86 USD 40.57%

Kõrge 22 USD

Madal 20 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Adaptive Biotechnologies Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Adaptive Biotechnologies Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

8.81 / 10.18Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.